It is not approved by any regulatory agency worldwide as of mid-2026
A Sanofi spokesperson told BioSpace in an emailed statement that the company made the strategic decision of focusing on offering the combination therapy Soliqua consisting of GLP-1 and basal insulin to help people manage their diabetes. The spokesperson added that Soliqua has since become one of the cornerstone therapies in its diabetes portfolio and represents an important growth asset for the company
Menor riesgo de efectos sistmicos (pancreatitis, hipoglucemia)
A clinical study of a GLP-1 RA highlighted that participants who followed dietary advice and injected weekly saw an average 18% lower energy intake compared to placebo, with significant reductions in body weight and cardio-metabolic risk
Nat Protoc 1(2):581585 Couto N, Wood J, Barber J (2016) The role of glutathione reductase and related enzymes on cellular redox homoeostasis network
For many who use them, GLP-1 meds have proven nothing short of a miracle leading not only to dramatic weight loss but to lower blood pressure and blood sugar levels in diabetics
